All In Biotech

Drug Trial Radar · NCT06451666

Safety and Efficacy Study of Pilocarpine HCl Ophthalmic Solution in Participants With Presbyopia

A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Pilocarpine HCl in Participants With Presbyopia

Last checked: Nov 19, 2026Latest source record: Jul 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

330

Planned (sponsor's estimate)

Start

Jun 30, 2024

Primary completion

Nov 30, 2025

Study completion Dec 30, 2025

Sponsor

Sponsor type
Industry
First posted
Jun 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to evaluate the efficacy, safety, and pharmacokinetics of pilocarpine HCl ophthalmic solution when administered bilaterally, once daily for 30 days in participants with presbyopia.

Conditions

  • Presbyopia

Interventions

  • Pilocarpine HCl Ophthalmic SolutionDrug

    Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days

  • VehicleDrug

    Vehicle, one drop in each eye, once daily, for up to 30 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Title: Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular Distance-Corrected Near Visual Acuity (DCNVA) at Day 30, Hour 3Time frame: Baseline (Day 1) to Day 30 (Hour 3)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.